LifeVantage Corporation

NasdaqCM:LFVN Voorraadrapport

Marktkapitalisatie: US$64.7m

LifeVantage Inkomsten in het verleden

Verleden criteriumcontroles 4/6

De winst van LifeVantage is gedaald met een gemiddeld jaarlijks percentage van -10.6%, terwijl de winst van de Personal Products -industrie jaarlijks groeide met 1.9%. De inkomsten zijn daalde met een gemiddeld percentage van 0.3% per jaar. Het rendement op het eigen vermogen LifeVantage bedraagt 23.8% en de nettomarge bedraagt 3.7%.

Belangrijke informatie

-10.60%

Groei van de winst

-5.93%

Groei van de winst per aandeel

Personal Products Groei van de industrie20.87%
Inkomstengroei-0.35%
Rendement op eigen vermogen23.83%
Nettomarge3.74%
Volgende winstupdate06 May 2026

Recente prestatie-updates uit het verleden

Recent updates

LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential

Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.

LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential

Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.

LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential

Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.

LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential

Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.

LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential

Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.

Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding

Feb 06
Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding

LFVN: Gut Health Research Progress Will Support Confident Upside Potential

Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).

LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential

Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).

LFVN: Gut Study Progress Will Drive Future Upside Potential

Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).

LFVN: Future Gut Health Research And Buybacks Will Drive Upside

Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.

LFVN: Future Index Inclusion Will Drive Upside Potential

Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).

LFVN: Share Repurchases and New Index Addition Will Drive Value

LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.

Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop

Nov 14
Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop

We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease

Nov 04
We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease

It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks

Sep 30
It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks

LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045

Sep 05
LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045

The LifeVantage Advantage: High Retention, High Returns

Jul 21

Shareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality

May 13
Shareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality

What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash

May 02
What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash
User avatar

New Initiatives Will Drive MindBody GLP-1 System's Future Success

Expansion into international markets and enhanced supply chain capacity are expected to drive significant revenue growth and stabilize future sales.

LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.04

Feb 09
LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.04

LifeVantage Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 07
LifeVantage Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

LifeVantage: Post-Earnings Sell-Off Provides Buying Opportunity

Feb 06

LifeVantage Corporation (NASDAQ:LFVN) Looks Just Right With A 33% Price Jump

Feb 05
LifeVantage Corporation (NASDAQ:LFVN) Looks Just Right With A 33% Price Jump

What Is LifeVantage Corporation's (NASDAQ:LFVN) Share Price Doing?

Feb 01
What Is LifeVantage Corporation's (NASDAQ:LFVN) Share Price Doing?

Market Participants Recognise LifeVantage Corporation's (NASDAQ:LFVN) Earnings Pushing Shares 31% Higher

Dec 20
Market Participants Recognise LifeVantage Corporation's (NASDAQ:LFVN) Earnings Pushing Shares 31% Higher

LifeVantage (NASDAQ:LFVN) Will Be Hoping To Turn Its Returns On Capital Around

Dec 16
LifeVantage (NASDAQ:LFVN) Will Be Hoping To Turn Its Returns On Capital Around

LifeVantage's (NASDAQ:LFVN) Dividend Will Be $0.04

Nov 16
LifeVantage's (NASDAQ:LFVN) Dividend Will Be $0.04

LifeVantage's (NASDAQ:LFVN) Dividend Will Be $0.04

Nov 02
LifeVantage's (NASDAQ:LFVN) Dividend Will Be $0.04

Opbrengsten en kosten

Hoe LifeVantage geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqCM:LFVN Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Dec 2521081570
30 Sep 25229101720
30 Jun 25229101710
31 Mar 2522291660
31 Dec 2421271580
30 Sep 2419641490
30 Jun 2420031540
31 Mar 2420541590
31 Dec 2321131640
30 Sep 2321331660
30 Jun 2321331660
31 Mar 23210-11650
31 Dec 22206-11630
30 Sep 2220501620
30 Jun 2220631610
31 Mar 2221091600
31 Dec 21212101620
30 Sep 21219141620
30 Jun 21220131640
31 Mar 21225121690
31 Dec 20229121720
30 Sep 20232121770
30 Jun 20233121790
31 Mar 20230121770
31 Dec 19230121770
30 Sep 1922781780
30 Jun 1922671780
31 Mar 1922471790
31 Dec 1821861740
30 Sep 1821061640
30 Jun 1820361580
31 Mar 1820031570
31 Dec 1719411540
30 Sep 1719411560
30 Jun 1719921620
31 Mar 1720241610
31 Dec 1621351670
30 Sep 1621661680
30 Jun 1620761590
31 Mar 1619941560
31 Dec 1518831490
30 Sep 1518431460
30 Jun 1519071480

Kwaliteitswinsten: LFVN heeft een hoog niveau van non-cash earnings.

Groeiende winstmarge: De huidige netto winstmarges (3.7%) LFVN } zijn hoger dan vorig jaar (3.5%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van LFVN is de afgelopen 5 jaar met 10.6% per jaar gedaald.

Versnelling van de groei: De winstgroei van LFVN over het afgelopen jaar ( 7.1% ) overtreft het 5-jarig gemiddelde ( -10.6% per jaar).

Winst versus industrie: De winstgroei LFVN over het afgelopen jaar ( 7.1% ) overtrof de Personal Products -sector 2.5%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 23.8% ) van LFVN wordt als hoog beschouwd.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/04/30 10:10
Aandelenkoers aan het einde van de dag2026/04/30 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/06/30

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

LifeVantage Corporation wordt gevolgd door 5 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Ilya ZubkovFreedom Broker
Mitchell PinheiroImperial Capital
Ryan MeyersLake Street Capital Markets, LLC